Supernus Pharmaceuticals, Inc. income statement

In fiscal 2025, Supernus Pharmaceuticals, Inc. reported revenue of $719m, up 8.6% on the year before, operating income of −$62.3m (a -8.7% margin) and net income of −$38.5m, or −$0.68 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Supernus Pharmaceuticals, Inc.: income statement, annual
Fiscal year	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	0	1	1	12	93	147	215	302	409	393	520	580	667	608	662	719	865
Cost of revenue	—	—	—	—	—	—	12	15	15	17	52	—	87	84	78	75	107
Gross profit	—	—	—	—	—	—	203	287	394	376	468	—	580	524	584	644	758
Research and development	35	31	24	17	20	29	43	50	89	69	76	90	75	92	109	106	122
Selling, general and administrative	5	8	20	56	73	89	106	138	155	153	201	305	377	336	322	486	509
Operating income	−40	−38	−42	−62	−5	21	54	100	144	149	174	86	46	−5	82	−62	−49
Interest expense	—	2	4	8	5	1	1	0	14	18	19	20	7	2	0	0	—
Income before tax	−39	−39	−46	−92	−10	15	50	101	140	147	169	73	61	3	98	−49	−43
Income tax	−0	−16	0	0	1	1	−41	43	29	34	42	20	0	1	24	−10	1
Net income	−38	54	−46	−92	−11	14	91	57	111	113	127	53	61	1	74	−39	−44
Diluted EPS	−$26.38	$31.39	−$2.72	−$2.90	−$0.26	$0.28	$1.76	$1.08	$2.05	$2.10	$2.36	$0.98	$1.04	$0.02	$1.32	−$0.68	−$0.76
Diluted shares (average)	2m	2m	17m	32m	42m	51m	52m	53m	54m	54m	54m	54m	62m	56m	56m	56m	58m
EBITDA	−39	−37	−41	−61	−4	22	57	108	152	155	192	119	132	80	162	29	3

US$ millions unless shown otherwise. Fiscal quarters.

Supernus Pharmaceuticals, Inc.: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	174	150	165	192	212	208	219	227
Cost of revenue	26	16	17	19	23	23	34	27
Gross profit	148	134	149	173	189	184	185	200
Research and development	29	27	22	29	28	39	29	26
Selling, general and administrative	79	90	94	180	122	125	134	128
Operating income	21	−10	12	−60	−4	−8	−58	21
Interest expense	0	—	0	0	0	—	2	1
Income before tax	26	−6	17	−58	−2	−6	−58	23
Income tax	11	6	−6	−13	2	−4	1	2
Net income	15	−12	22	−45	−4	−2	−58	21
Diluted EPS	$0.27	−$0.21	$0.40	−$0.80	−$0.07	−$0.04	−$1.01	$0.35
EBITDA	40	10	13	−60	21	18	−58	22

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AXSM vs SUPN CORT vs SUPN HRMY vs SUPN

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Supernus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Supernus Pharmaceuticals, Inc.